<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514044</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-14-0354</org_study_id>
    <nct_id>NCT02514044</nct_id>
  </id_info>
  <brief_title>Dextroamphetamine and tDCS to Improve the Fluency</brief_title>
  <official_title>Transcranial Direct Current Stimulation and Melodic Intonation Therapy Combined With Dextroamphetamine in Chronic Stroke Patients With Non-fluent Aphasia; Safety and Efficacy Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study aims to evaluate safety and efficacy of combined dextroamphetamine
      (Dexedrine) and transcranial direct current stimulation (tDCS) with melodic intonation
      therapy (MIT) for treatment of aphasia after stroke. The target population is patients with
      chronic speech deficits due to a left hemisphere non-hemorrhagic stroke. Findings from this
      proposed project will help in the design of future larger studies.The safety phase will use
      cross-over, placebo controlled and single-blinded design. 10 participants with post stroke
      chronic non-fluent aphasia will undergo two experiments. To study the safety and effect of
      combined dextroamphetamine, tDCS and MIT therapy the study will use a parallel-groups,
      randomized, sham and placebo controlled, and double-blinded design in which 48 participants
      with post stroke chronic non-fluent aphasia will be randomly assigned to receive either 1)
      dextroamphetamine therapy with active stimulation, 2) placebo medication with active
      stimulation, 3) dextroamphetamine therapy with sham stimulation or 4) placebo medication with
      sham stimulation for the same duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two phases were planned for this study, as described below. The safety phase of the study was
      completed; however, due to limited funding, the efficacy phase was never started (that is,
      the efficacy phase was terminated).

      SAFETY PHASE: The safety phase will use cross-over, placebo controlled and single-blinded
      design. 10 participants with post stroke chronic non-fluent aphasia will undergo two
      experiments. In the experiment 1, the subjects will receive 10 mg dextroamphetamine, 1.5 mA
      anodal tDCS to right inferior frontal gyrus (right Broca's area), and melodic intonation
      therapy. The two experiments of one time intervention will be separated by 1 week of washout
      and when the subjects come back for experiment 2, any later side effects will be evaluated.
      In the experiment 2, the subjects will receive placebo medication with anodal tDCS to right
      IFG (Broca's area) and melodic intonation therapy. During the experiments, thirty minutes
      before stimulation, participants in the active drug experiment (n=10) will take 10 mg
      dextroamphetamine per oral -experiment 1- and participants in the placebo drug experiment
      will take placebo pill per oral -experiment 2-. During the 20 minute stimulation phase, the
      participants (n=10) will receive anodal tDCS (1.5 mA) on ipsilesional right inferior frontal
      gyrus (Broca's area). All participants will simultaneously receive melodic intonation therapy
      for duration of an hour during and after 20 minutes of stimulation.

      EFFICACY PHASE: To study the safety and effect of combined dextroamphetamine, tDCS and MIT
      therapy the study will use a parallel-groups, randomized, sham and placebo controlled, and
      double-blinded design in which 48 participants with post stroke chronic non-fluent aphasia
      will be randomly assigned to receive either 1) dextroamphetamine therapy with active
      stimulation, 2) placebo medication with active stimulation, 3) dextroamphetamine therapy with
      sham stimulation or 4) placebo medication with sham stimulation for the same duration. The
      subjects from the previous step of the study will be asked to participate to this step.
      Thirty minutes before stimulation participants in the active drug groups, group 1 (n=12) and
      group 3 (n=12) will take dextroamphetamine 10 mg per oral and participants in the placebo
      groups, group 2 (n=12) and group 4 (n=12) will take placebo pill per oral. During the 20
      minute stimulation phase, the participants in the active stimulation groups, groups 1 (n=12)
      and 2 (n=12) will receive anodal tDCS (1.5 mA) on right inferior frontal gyrus (Broca's
      area), and participants in the sham control groups, group 3 (n=12) and group 4 (n=12) will
      receive sham stimulation. All participants will simultaneously receive melodic intonation
      therapy for duration of an hour during and after 20 minutes of stimulation. Treatment will be
      administered at an intensity of 5 sessions per week for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Language Quotient as Assessed by the Western Aphasia Battery</measure>
    <time_frame>immediately before the treatment, immediately after the treatment</time_frame>
    <description>The score on the Language Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery</measure>
    <time_frame>immediately before the treatment, immediately after the treatment</time_frame>
    <description>The score on the Aphasia Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Boston Diagnostic Aphasia Examination</measure>
    <time_frame>Baseline,2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boston Diagnostic Aphasia Examination</measure>
    <time_frame>Baseline,2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Blood Pressure</measure>
    <time_frame>immediately before the treatment, after after the treatment</time_frame>
    <description>Non-invasive BP measurements performed by a clinician before and after each experiment.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Dexedrine+sham tDCS+speech therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Dexedrine and speech therapy for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active tDCS+placebo+speech therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mA anodal tDCS and speech therapy for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexedrine+tDCS+speech therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham stimulation+placebo+speech therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sham stimulation, placebo and speech therapy for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexedrine+tDCS+Speech Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+tDCS+Speech Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mA anodal tDCS, and speech therapy for 1 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexedrine</intervention_name>
    <description>10 mg immediate release of Dexedrine</description>
    <arm_group_label>Dexedrine+sham tDCS+speech therapy</arm_group_label>
    <arm_group_label>Dexedrine+tDCS+Speech Therapy</arm_group_label>
    <arm_group_label>Dexedrine+tDCS+speech therapy</arm_group_label>
    <other_name>Adderall, Dexedrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active tDCS</intervention_name>
    <description>1.5 mA tDCS anodal tDCS</description>
    <arm_group_label>Dexedrine+tDCS+Speech Therapy</arm_group_label>
    <arm_group_label>Dexedrine+tDCS+speech therapy</arm_group_label>
    <arm_group_label>active tDCS+placebo+speech therapy</arm_group_label>
    <arm_group_label>placebo+tDCS+Speech Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Speech Therapy</intervention_name>
    <description>60 min of speech therapy</description>
    <arm_group_label>Dexedrine+sham tDCS+speech therapy</arm_group_label>
    <arm_group_label>Dexedrine+tDCS+Speech Therapy</arm_group_label>
    <arm_group_label>Dexedrine+tDCS+speech therapy</arm_group_label>
    <arm_group_label>active tDCS+placebo+speech therapy</arm_group_label>
    <arm_group_label>placebo+tDCS+Speech Therapy</arm_group_label>
    <arm_group_label>sham stimulation+placebo+speech therapy</arm_group_label>
    <other_name>Melodic Intonation Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>active tDCS+placebo+speech therapy</arm_group_label>
    <arm_group_label>placebo+tDCS+Speech Therapy</arm_group_label>
    <arm_group_label>sham stimulation+placebo+speech therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <arm_group_label>Dexedrine+sham tDCS+speech therapy</arm_group_label>
    <arm_group_label>sham stimulation+placebo+speech therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 18

          -  Native English proficiency;

          -  Nonfluent speech;

          -  Premorbid right handedness;

          -  Non-hemorrhagic left hemispheric stroke at least 6 months prior to the investigation.

          -  No contraindications for MRI (only subjects who will undergo MRI scan).

        Exclusion Criteria:

          -  Hypersensitivity or idiosyncrasy to dextroamphetamine or to other sympathomimetic
             agents;

          -  Pregnant or trying to become pregnant;

          -  Active alcohol abuse, illicit drug use or drug abuse or significant mental illness;

          -  Subjects receiving alpha adrenergic antagonists or agonists;

          -  Any history of epilepsy;

          -  Any condition that would prevent the subject from giving voluntary informed consent;

          -  An implanted brain stimulator;

          -  Aneurysm clip or other metal in the brain;

          -  Enrolled or plans to enroll in an interventional trial during this study;

          -  Scalp wounds or infections;

          -  Previous stroke with residual deficits (TIAs not a reason for exclusion);

          -  A concurrent progressive neurologic disorder, acute coronary syndrome, severe heart
             disease (NYHA Classification &gt; 3), or other major medical condition;

          -  Advanced atherosclerosis, Unstable cardiac dysrhythmia or uncontrolled hypertension
             (&gt;160/100 mm Hg), or untreated hyperthyroidism;

          -  Diagnosis of glaucoma

          -  During or within 14 days following the administration of monoamine oxidase inhibitors;

          -  Subjects requiring palliative care;

          -  Terminal medical condition such as AIDS or cancer;

          -  Subjects unable to comprehend or follow verbal commands;

          -  Based on PI's or local physician's assessment patient unable to tolerate the trial
             procedure due to medical condition;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard E Francisco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center at Houston, Department of Physical Medicine and Rehabilitation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <results_first_submitted>May 3, 2018</results_first_submitted>
  <results_first_submitted_qc>July 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2018</results_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Gerard Francisco</investigator_full_name>
    <investigator_title>Chairman and Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adderall</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap</title>
          <description>10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day Dexedrine: 10 mg immediate release of Dexedrine Active tDCS: 1.5 mA tDCS anodal tDCS Speech Therapy: 60 min of speech therapy
Placebo, 1.5 mA anodal tDCS, and speech therapy for 1 day Active tDCS: 1.5 mA tDCS anodal tDCS Speech Therapy: 60 min of speech therapy Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dexedrine+tDCS+Speech Therapy (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Placebo+tDCS+Speech Therapy (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day Dexedrine: 10 mg immediate release of Dexedrine Active tDCS: 1.5 mA tDCS anodal tDCS Speech Therapy: 60 min of speech therapy
Placebo, 1.5 mA anodal tDCS, and speech therapy for 1 day Active tDCS: 1.5 mA tDCS anodal tDCS Speech Therapy: 60 min of speech therapy Placebo</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-fluent aphasia assessed by clinicians</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Language Quotient as Assessed by the Western Aphasia Battery</title>
        <description>The score on the Language Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported.</description>
        <time_frame>immediately before the treatment, immediately after the treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexedrine+tDCS+Speech Therapy</title>
            <description>The subjects received 10 mg D-AMP 30 minutes before the 60 minutes of SLT; first 20 min is simultaneous tDCS stimulation in this experiment/arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+tDCS+Speech Therapy</title>
            <description>The subjects received placebo 30 minutes before the 60 minutes of SLT; first 20 min is simultaneous tDCS stimulation in this experiment/arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Language Quotient as Assessed by the Western Aphasia Battery</title>
          <description>The score on the Language Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported.</description>
          <units>percent change in language quotient</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.02" lower_limit="3.22" upper_limit="18.81"/>
                    <measurement group_id="O2" value="-4.2" lower_limit="-10.57" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We tested normality using the Kolmogorov-Smirnov (KS) test for all reported measures. We compared scores of Bedside WAB-R® subtests Bedside WAB-R® AQ and LQ from before the study intervention and after the intervention in both experiments by using a two-tailed and paired t-test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>We also performed normalization by calculating the dependent variable as the percentage of change (&quot;proportional change&quot;) as it follows; (1) (post-active values - pre-active values)/ (pre-active values) and (2) (post-placebo values - pre-placebo values)/ (pre-placebo series). We compared the percentage of change in Bedside WAB-R® aphasia and language quotients and blood pressures for the experiments with active- and placebo drugs combined active tDCS with MIT using a two-tailed paired t-test.</non_inferiority_desc>
            <p_value>0.008</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery</title>
        <description>The score on the Aphasia Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported.</description>
        <time_frame>immediately before the treatment, immediately after the treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexedrine+tDCS+Speech Therapy</title>
            <description>10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
Dexedrine: 10 mg immediate release of Dexedrine
Active tDCS: 1.5 mA tDCS anodal tDCS
Speech Therapy: 60 min of speech therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo+tDCS+Speech Therapy</title>
            <description>1.5 mA anodal tDCS, and speech therapy for 1 day
Active tDCS: 1.5 mA tDCS anodal tDCS
Speech Therapy: 60 min of speech therapy
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery</title>
          <description>The score on the Aphasia Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported.</description>
          <units>percent change in aphasia quotient</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="1.49" upper_limit="14.31"/>
                    <measurement group_id="O2" value="-.02" lower_limit="-7.63" upper_limit="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We tested normality using the Kolmogorov–Smirnov (KS) test for all reported measures. We compared scores of Bedside WAB-R® subtests Bedside WAB-R® AQ and LQ from before the study intervention and after the intervention in both experiments by using a two-tailed and paired t-test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>We also performed normalization by calculating the dependent variable as the percentage of change (“proportional change”) as it follows; (1) (post-active values – pre-active values)/ (pre-active values) and (2) (post-placebo values – pre-placebo values)/ (pre-placebo series). We compared the percentage of change in Bedside WAB-R® aphasia and language quotients and blood pressures for the experiments with active- and placebo drugs combined active tDCS with MIT using a two-tailed paired t-test.</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Boston Diagnostic Aphasia Examination</title>
        <time_frame>Baseline,2 weeks</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexedrine+tDCS+Speech Therapy</title>
            <description>10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
Dexedrine: 10 mg immediate release of Dexedrine
Active tDCS: 1.5 mA tDCS anodal tDCS
Speech Therapy: 60 min of speech therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo+tDCS+Speech Therapy</title>
            <description>1.5 mA anodal tDCS, and speech therapy for 1 day
Active tDCS: 1.5 mA tDCS anodal tDCS
Speech Therapy: 60 min of speech therapy
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Boston Diagnostic Aphasia Examination</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Boston Diagnostic Aphasia Examination</title>
        <time_frame>Baseline,2 months</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexedrine+tDCS+Speech Therapy</title>
            <description>10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
Dexedrine: 10 mg immediate release of Dexedrine
Active tDCS: 1.5 mA tDCS anodal tDCS
Speech Therapy: 60 min of speech therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo+tDCS+Speech Therapy</title>
            <description>1.5 mA anodal tDCS, and speech therapy for 1 day
Active tDCS: 1.5 mA tDCS anodal tDCS
Speech Therapy: 60 min of speech therapy
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Boston Diagnostic Aphasia Examination</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Blood Pressure</title>
        <description>Non-invasive BP measurements performed by a clinician before and after each experiment.</description>
        <time_frame>immediately before the treatment, after after the treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexedrine+tDCS+Speech Therapy</title>
            <description>10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
Dexedrine: 10 mg immediate release of Dexedrine
Active tDCS: 1.5 mA tDCS anodal tDCS
Speech Therapy: 60 min of speech therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo+tDCS+Speech Therapy</title>
            <description>1.5 mA anodal tDCS, and speech therapy for 1 day
Active tDCS: 1.5 mA tDCS anodal tDCS
Speech Therapy: 60 min of speech therapy
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Blood Pressure</title>
          <description>Non-invasive BP measurements performed by a clinician before and after each experiment.</description>
          <units>percent change in blood pressure</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="3"/>
                    <measurement group_id="O2" value="4" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="5"/>
                    <measurement group_id="O2" value="5" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D-AMP+tDCS+Speech Therapy</title>
          <description>The subjects received 10 mg of D-AMP medication 30 minutes before the simultaneous tDCS (first 20 min) and 60 min of SLT in this experiment.</description>
        </group>
        <group group_id="E2">
          <title>Placebo+tDCS+Speech Therapy</title>
          <description>The subjects received placebo medication 30 minutes before the simultaneous tDCS (first 20 min) and 60 min of SLT in this experiment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Headache</sub_title>
                <description>Resolved shortly after</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mild Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Non-significant skin redness and tingling</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The safety phase of the study was completed; however, the efficacy phase was not started.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Gerard E. Francisco, Chairman and Professor, Physical Medicine and Rehabilitation</name_or_title>
      <organization>University of Texas Health Science Center at Houston (UTHealth)</organization>
      <phone>713.797.5246</phone>
      <email>gerard.e.francisco@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

